#United States #CML #Boulder #Enliven Therapeutics #ELVN-001

Enliven Therapeutics Financial Update and Future Outlook

Enliven Therapeutics, Inc. (Nasdaq: ELVN), a biopharmaceutical company dedicated to developing effective therapies for chronic myeloid leukemia (CML), recently released its financial results for the fourth quarter and full year of 2025. With significant advancements in its drug pipeline, the company appears poised for growth in 2026 and beyond.

The company's ELVN-001 program has shown promising results, particularly in the ongoing Phase 1b ENABLE clinical trial. This trial evaluates the drug in CML patients who are relapsed, refractory, or intolerant to existing tyrosine kinase inhibitors (TKIs). Initial data from the trial have been encouraging, suggesting that ELVN-001 could be a best-in-class treatment option for patients struggling with this difficult-to-manage disease.

Positive Data from ELVN-001

As of December 22, 2025, the trial has enrolled 60 patients in its initial cohorts, with a significant portion of this group having extensive prior treatment histories. Notably, 53% of these patients had received four or more unique TKIs. The early results are promising, showing substantial Major Molecular Response (MMR) rates at 24 weeks:

• - For the 80 mg cohort: 47% achieved cumulative MMR.
• - For those addressing doses of 60 mg and 120 mg: the MMR rates surged to 69%.

Moreover, many of the patients in the trial maintained their responses, a crucial indicator of the drug's long-term effectiveness. These findings are paving the way for an anticipated Phase 3 pivotal trial, dubbed ENABLE-2, expected to commence in the latter half of 2026.

Financial Snapshot

Enliven reported a cash position of $462.6 million as of the end of 2025, which will sustain its operations into the first half of 2029. This robust financial standing positions the company well as it moves into more advanced stages of clinical trials. Additionally, research and development (R&D) expenses grew slightly to $21.2 million in the fourth quarter, compared to $20.7 million in 2024, reflecting the ongoing investment in its drug development processes.

General and administrative (G&A) expenses rose significantly, reaching $13 million in the fourth quarter, mainly due to costs associated with leadership transitions. Overall, Enliven reported a net loss of $29.7 million for Q4 2025, up from a loss of $23.2 million in the same quarter of the previous year. The total net loss for the year was $103.7 million, compared to $89 million in 2024.

Leadership Changes and Future Directions

The transition in leadership, with Rick Fair taking the reins as CEO in December 2025, aligns with Enliven's shift toward late-stage development and commercial readiness. The company is dedicated to ensuring it has the expertise necessary to navigate this critical phase of growth. Additionally, the introduction of Scott Garland to the Board illustrates a commitment to bolstering governance structures during a transformative period for the company.

Looking Ahead

As Enliven Therapeutics enters 2026, it stands on the precipice of pivotal developments in the clinical landscape. With key readouts and regulatory interactions scheduled throughout the year, including a mid-year update on the ongoing Phase 1 data, there is significant anticipation surrounding ELVN-001’s potential impact on CML care.

In summary, Enliven Therapeutics is making noteworthy strides in both its financial and research aspects, setting a solid foundation for the launch of its Phase 3 clinical trials and, ultimately, for potential commercialization. The coming months will be critical as the company works to fulfill its vision of delivering innovative therapies to improve the lives of patients with CML.